Is Semaglutide Being Misused? What the FDA's Side Effect Database Shows
The FDA's adverse event database shows significantly higher misuse signals for semaglutide than other GLP-1 drugs — including use without prescriptions and drug abuse reports — though the signal is comparable to other weight loss medications.
Quick Facts
What This Study Found
Semaglutide showed significantly higher signals for misuse-related adverse events compared to other GLP-1 drugs. Its proportional reporting ratios (PRR) for 'drug abuse' (4.05), 'drug withdrawal syndrome' (4.05), 'prescription drug used without a prescription' (3.60), and 'intentional product use issue' (1.80) were all significantly elevated (p<0.01) versus other GLP-1 receptor agonists.
However, when compared to the phentermine-topiramate combination (an established weight loss drug with known misuse potential), semaglutide showed no significant differences in misuse signals. This suggests semaglutide's misuse signal may be in line with other weight loss medications rather than uniquely problematic.
Key Numbers
31,542 total AERs (Jan 2018–Dec 2022) · semaglutide: 8,249 reports (26.1%) · dulaglutide: 11,858 (37.6%) · semaglutide vs other GLP-1s: PRR 4.05 for drug abuse · PRR 4.05 for withdrawal · PRR 3.60 for use without prescription · all p<0.01
How They Did This
Descriptive pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database from January 2018 through December 2022. Researchers extracted all adverse event reports for seven GLP-1 receptor agonists and the phentermine-topiramate combination. Misuse-related events were identified using specific adverse event terms. Reporting odds ratios (ROR) and proportional reporting ratios (PRR) were calculated to detect safety signals.
Why This Research Matters
As semaglutide went viral as a weight loss drug, reports emerged of people using it cosmetically without medical need, obtaining it without prescriptions, and diverting it from diabetic patients. This is the first study to formally quantify misuse signals in pharmacovigilance data. The findings raise questions about how to balance expanded access with appropriate use monitoring.
The Bigger Picture
The semaglutide misuse question sits at the intersection of public health, media culture, and pharmaceutical regulation. When a prescription drug goes viral on social media, demand can outstrip appropriate use. This study provides early evidence that the cultural buzz around semaglutide has translated into measurable misuse signals in pharmacovigilance data — though whether this represents a genuine safety problem or an artifact of media-driven reporting bias remains to be determined.
What This Study Doesn't Tell Us
FAERS is a voluntary reporting system with well-known limitations: under-reporting, reporting bias (media attention on semaglutide likely inflated reports), and inability to establish causation. The 'drug abuse' and 'misuse' adverse event categories in FAERS are broad and may include cases of off-label use that aren't truly misuse. The study can't distinguish between recreational misuse and cosmetic off-label use by non-obese individuals. Media coverage of semaglutide may have disproportionately influenced reporting.
Questions This Raises
- ?Are the elevated misuse signals driven by genuine misuse, or by the massive media attention that increased all reporting about semaglutide?
- ?Should semaglutide prescribing be more tightly regulated, or would that restrict access for patients who genuinely need it?
- ?Do the 'withdrawal syndrome' reports indicate a physiological dependence, or are they reflecting rebound weight gain after discontinuation?
Trust & Context
- Key Stat:
- PRR 4.05 for drug abuse reports Semaglutide had 4 times more 'drug abuse' reports proportionally than other GLP-1 receptor agonists in the FDA adverse event database (2018–2022)
- Evidence Grade:
- Pharmacovigilance data from FAERS provides early safety signals but is highly susceptible to reporting bias — especially for drugs with enormous media attention. The elevated signals are concerning but could be artifacts of increased reporting rather than increased misuse. Low-moderate evidence that requires confirmation from empirical studies.
- Study Age:
- Published in 2023 with data through December 2022. Since then, semaglutide prescriptions have continued to surge and tirzepatide has gained significant market share. More recent pharmacovigilance data would likely show different patterns.
- Original Title:
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 16(7) (2023)
- Authors:
- Chiappini, Stefania, Vickers-Smith, Rachel, Harris, Daniel, Papanti Pelletier, G Duccio, Corkery, John Martin, Guirguis, Amira, Martinotti, Giovanni, Sensi, Stefano L, Schifano, Fabrizio
- Database ID:
- RPEP-06795
Evidence Hierarchy
Frequently Asked Questions
Does this mean semaglutide is addictive?
Not necessarily. The 'drug abuse' and 'withdrawal' categories in the FDA database are broad and can include cases of off-label use by people without obesity or diabetes. The 'withdrawal' reports may reflect rebound weight gain or appetite return after stopping the drug, rather than a physiological addiction. More research is needed to understand what these signals actually represent.
Is it dangerous to use semaglutide without a prescription?
Yes, it can be. Without medical supervision, patients may not be properly screened for contraindications (like a history of medullary thyroid cancer or pancreatitis), may dose incorrectly, or may not be monitored for side effects like dehydration or gallbladder problems. Obtaining prescription drugs through unofficial channels also carries risks of counterfeit products.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-06795APA
Chiappini, Stefania; Vickers-Smith, Rachel; Harris, Daniel; Papanti Pelletier, G Duccio; Corkery, John Martin; Guirguis, Amira; Martinotti, Giovanni; Sensi, Stefano L; Schifano, Fabrizio. (2023). Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.. Pharmaceuticals (Basel, Switzerland), 16(7). https://doi.org/10.3390/ph16070994
MLA
Chiappini, Stefania, et al. "Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.." Pharmaceuticals (Basel, 2023. https://doi.org/10.3390/ph16070994
RethinkPeptides
RethinkPeptides Research Database. "Is There a Risk for Semaglutide Misuse? Focus on the Food an..." RPEP-06795. Retrieved from https://rethinkpeptides.com/research/chiappini-2023-is-there-a-risk
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.